SAN

74.115

-4.79%↓

SRT3

223.85

+3.01%↑

ORNBV.FI

68.5

+3.4%↑

SAN

74.115

-4.79%↓

SRT3

223.85

+3.01%↑

ORNBV.FI

68.5

+3.4%↑

SAN

74.115

-4.79%↓

SRT3

223.85

+3.01%↑

ORNBV.FI

68.5

+3.4%↑

SAN

74.115

-4.79%↓

SRT3

223.85

+3.01%↑

ORNBV.FI

68.5

+3.4%↑

SAN

74.115

-4.79%↓

SRT3

223.85

+3.01%↑

ORNBV.FI

68.5

+3.4%↑

Search

Fagron

Avatud

SektorTervishoid

24 0.84

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

23.85

Max

24

Põhinäitajad

By Trading Economics

Sissetulek

-99K

45M

Müük

-98K

476M

P/E

Sektori keskmine

19.113

67.147

Dividenditootlus

1.69

Kasumimarginaal

9.55

Töötajad

4,193

EBITDA

11M

98M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+20.59% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.69%

2.36%

Järgmine tulemuste avaldamine

30. juuli 2026

Turustatistika

By TradingEconomics

Turukapital

109M

1.7B

Eelmine avamishind

23.16

Eelmine sulgemishind

24

Uudiste sentiment

By Acuity

50%

50%

176 / 347 Pingereas Healthcare

Fagron Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. mai 2026, 22:17 UTC

Tulu

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4. mai 2026, 23:47 UTC

Tulu

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4. mai 2026, 23:45 UTC

Tulu

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4. mai 2026, 23:45 UTC

Tulu

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4. mai 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

4. mai 2026, 22:44 UTC

Omandamised, ülevõtmised, äriostud

Regis: Jim Beyer To Be Chief Executive of Combined Company

4. mai 2026, 22:43 UTC

Omandamised, ülevõtmised, äriostud

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4. mai 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4. mai 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4. mai 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4. mai 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4. mai 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Regis: Shareholders to Own About 51% of Combined Company

4. mai 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Regis: Board Unanimously Endorsed, Supported Deal

4. mai 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Regis: Deal Unanimously Recommended by Vault Board

4. mai 2026, 22:39 UTC

Omandamised, ülevõtmised, äriostud

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4. mai 2026, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Regis Resources to Acquire All Ordinary Shares in Vault

4. mai 2026, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Regis Resources, Vault Minerals Agree to Merger of Equals

4. mai 2026, 22:37 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4. mai 2026, 22:26 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4. mai 2026, 22:02 UTC

Tulu

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4. mai 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4. mai 2026, 21:52 UTC

Tulu

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4. mai 2026, 21:50 UTC

Tulu

Westpac: Some Sectors More Affected Than Others>WBC.AU

4. mai 2026, 21:50 UTC

Tulu

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4. mai 2026, 21:49 UTC

Tulu

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4. mai 2026, 21:44 UTC

Tulu

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4. mai 2026, 21:44 UTC

Tulu

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4. mai 2026, 21:43 UTC

Tulu

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4. mai 2026, 21:41 UTC

Tulu

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4. mai 2026, 21:40 UTC

Tulu

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Võrdlus sarnastega

Hinnamuutus

Fagron Prognoos

Hinnasiht

By TipRanks

20.59% tõus

12 kuu keskmine prognoos

Keskmine 19.5 EUR  20.59%

Kõrge 19.5 EUR

Madal 19.5 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Fagron 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

1

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

176 / 347 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
help-icon Live chat